Avik Pharmaceuticals

Mumbai, India Founded: 1980 • Age: 46 yrs
Manufactures corticosteroids and steroid APIs for pharmaceutical industry.

About Avik Pharmaceuticals

Avik Pharmaceuticals is a Healthcare company based in Mumbai (India) founded in 1980 by Anant Thakore. It manufactures corticosteroids and steroid APIs for pharmaceutical industry. It operates on a B2B model. The company has 174 employees. Its chief executive, as recorded, is Anant Thakore. Its Indian entity Avik Pharmaceutical Limited reported revenue of β‚Ή103 Cr. Avik Pharmaceuticals offers products and services including Beclomethasone Dipropionate, Betamethasone Dipropionate, Budesonide, Clobetasol 17 Propionate, and Testosterone. Its focus areas include Pharmaceuticals, API Manufacturing, Steroids and Hormones. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

Avik Pharmaceutical Limited is an RD-based company specializing in the production of active pharmaceutical ingredients, primarily corticosteroids, since the 1980s. It operates manufacturing facilities in Vapi, Gujarat, near Mumbai, India, focusing on steroids and hormones. The company supplies these products to various pharmaceutical entities, emphasizing quality and innovation in API development.

  • Headquarters Mumbai, India
  • Employees 174
  • Founders Anant Thakore
  • Sectors
    Healthcare
  • Website avikpharma.com
  • Legal Name Avik Pharmaceutical Limited
  • Date of Incorporation 25 Sep, 1979
  • Jurisdiction Mumbai, Maharashtra, India
Key Metrics
  • Annual Revenue
    ₹103 Cr

    FY 2025 · +29% YoY

  • Net Profit
    ₹15.58 Cr

    FY 2025 · 15% margin

  • EBITDA
    ₹24.95 Cr

    FY 2025 · 24% margin

  • Employee Count
    174

Products & Services of Avik Pharmaceuticals

Avik Pharmaceuticals offers a comprehensive portfolio of products and services, including Beclomethasone Dipropionate, Betamethasone Dipropionate, Budesonide, Clobetasol 17 Propionate, and Testosterone.

Beclomethasone Dipropionate
Steroid

Corticosteroid API used in respiratory treatments.

Betamethasone Dipropionate
Steroid

Anti-inflammatory steroid for skin conditions.

Budesonide
Steroid

Corticosteroid for asthma and allergy management.

Clobetasol 17 Propionate
Steroid

Topical steroid for severe skin inflammation.

Testosterone
Hormone

Steroidal hormone for medical hormone therapy.

Norethisterone Base
Hormone

Progestin used in contraceptives and treatments.

Board of directors of Avik Pharmaceutical Limited (Avik Pharmaceuticals)

Avik Pharmaceutical Limited is the primary company behind Avik Pharmaceuticals. The board of Avik Pharmaceutical Limited currently have 6 directors; the longest-serving is Anant Rajendralal Thakore, appointed in 1979. 9 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Anant Rajendralal Thakore
DIN 00095066
Managing Director25 Sep 197947 yrs 1 moAvik Pharmaceutical Limited
Jeevan Lal Nagori
DIN 00017939
Director18 Nov 201312 yrs 11 moAvik Pharmaceutical Limited
Neha Anant Thakore
DIN 00893957
Whole-time director04 Jan 20224 yrs 9 moAvik Pharmaceutical Limited
Raj Kamal Prasad Verma
DIN 02166789
Director16 Sep 20242 yrs 1 moAvik Pharmaceutical Limited
Sushil Kumar Kumra
DIN 08676523
Director16 Sep 20242 yrs 1 moAvik Pharmaceutical Limited
Rajeshree Maruti Chougule
DIN 10647042
Company Secretary19 Dec 20241 yr 10 moAvik Pharmaceutical Limited

People of Avik Pharmaceuticals

1 people are tracked at Avik Pharmaceuticals (1 in leadership); the tracked headcount is 174.

NameRoleGroup
Founder, CEOLeadership
Premium access

Complete people profiles for Avik Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Avik Pharmaceuticals

Figures of Avik Pharmaceutical Limited, the primary company behind Avik Pharmaceuticals, for FY 2025. Revenue was ₹103 Cr (+29% year on year). Net profit was ₹15.58 Cr (15% margin). EBITDA was ₹24.95 Cr (24% margin). Revenue has grown at a compounded annual rate of +17% over three years.

  • ₹103 CrRevenue · FY 2025 · +29% YoY
  • ₹15.58 CrNet profit · 15% margin
  • ₹24.95 CrEBITDA · 24% margin
  • ₹10.88 CrPaid-up capital
  • 174Employees (provident fund records)
  • +17%Revenue CAGR, 3 years

Balance sheet, profit and loss, cash flow and ratios of Avik Pharmaceutical Limited are on its company page.

Premium access

Detailed financial statements for Avik Pharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Similar companies to Avik Pharmaceuticals

Avik Pharmaceuticals has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed similar companies of Avik Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Avik Pharmaceuticals

The website of Avik Pharmaceuticals (avikpharma.com) receives about 1.2K visits a month.

  • Monthly visits
    1.2K

    ▲ 280% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Avik Pharmaceuticals

Avik Pharmaceuticals was founded in 1980.

Avik Pharmaceuticals is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Anant Thakore is the CEO of Avik Pharmaceuticals, as recorded in our data. They have also founded this company.

Avik Pharmaceuticals has 174 employees.

The primary company behind Avik Pharmaceuticals, Avik Pharmaceutical Limited, reported revenue of β‚Ή103 Cr for FY 2025, up 29% year on year.

Avik Pharmaceutical Limited is an RD-based company specializing in the production of active pharmaceutical ingredients, primarily corticosteroids, since the 1980s. It operates manufacturing facilities in Vapi, Gujarat, near Mumbai, India, focusing on steroids and hormones. The company supplies these products to various pharmaceutical entities, emphasizing quality and innovation in API development.

Avik Pharmaceuticals's top competitors include Laurus Labs, Symbiotec and SeQuent.

Avik Pharmaceuticals offers Beclomethasone Dipropionate, Betamethasone Dipropionate, Budesonide, Clobetasol 17 Propionate, and 2 more products and services.

Avik Pharmaceuticals operates through Avik Pharmaceutical Limited.

The legal entities of Avik Pharmaceuticals currently have 7 directors, including Jeevan Lal Nagori, Anant Rajendralal Thakore, Neha Anant Thakore and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available